HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Panobinostat | Farydak | 20 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
J2502 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
C9454 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
NA | Pazopanib | Votrient | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT, Lck, FMS | Yes | 2009 | In Use | |||
J9266 | Pegaspargase | Oncaspar | unspecified | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1996 | In Use | ||
J2505 | Pegfilgrastim | Neulasta:Neulasta Onpro | 6 mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2002 | Jan 1, 2004 | Jan 26, 2022 | No Longer Used | |
Q5122 | Pegfilgrastim-apgf | Nyvepria | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony Stimulating Factor | No | 2020 | Jan 1, 2021 | In Use | ||
C9058 | Pegfilgrastim-bmez | Ziextenzo | 0.5mg | Ancillary Therapy | immunomodulatorne | Granulocyte Colony Stimulating Factor | No | 2019 | Mar 31, 2020 | Jul 1, 2020 | No Longer Used | |
Q5111 | Pegfilgrastim-cbqv | Udenyca | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2019 | Jan 1, 2019 | In Use | ||
Q5130 | Pegfilgrastim-pbbk | Fylnetra | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | Mar 17, 2023 | In Use | ||
J2506 | Pegfilgratim (ex Biosimilars) | Neulasta | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2002 | Jan 26, 2022 | In Use | ||
Q5120 | Pegfilgratim-bmez | Ziextenzo | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony Stimulating Factor | No | 2019 | Jul 1, 2020 | In Use | ||
Q5127 | Pegflilgrastim-fpgk | Stimufend | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | Mar 17, 2023 | In Use | ||
S0145 | Pegintereferon Alfa-2a | Pegasys | 180 mcg/mL | Immunotherapy | Cytokine | Interferon | No | 2002 | Jul 1, 2005 | In Use | ||
S0146 | Peginterferon Alfa-2b | Pegintron, Sylatron | 20 mcg/mL | Immunotherapy | Cytokine | Interferon | No | 2001 | Jul 1, 2005 | Sep 30, 2010 | No Longer Used | |
J9271 | Pembrolizumab | Keytruda | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan 1, 2016 | In Use | ||
C9027 | Pembrolizumab | Keytruda | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan 1, 2015 | Dec 31, 2015 | No Longer Used | |
C9213 | Pemetrexed | Alimta | 10 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2004 | Feb 4, 2004 | Dec 31, 2004 | No Longer Used | |
J9304 | Pemetrexed | Pemfexy | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2020 | Oct 1, 2020 | In Use | ||
J9305 | Pemetrexed | Alimta | 10 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2004 | Jan 1, 2005 | In Use | ||
J9296 | Pemetrexed (Accord) | Pemetrexed (Accord) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Mar 17, 2023 | In Use | ||
J9322 | Pemetrexed (Bluepoint) | Pemetrexed (Bluepoint) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Jul 11, 2023 | In Use | ||
J9294 | Pemetrexed (Hospira) | Pemetrexed (Hospira) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Mar 17, 2023 | In Use | ||
J9297 | Pemetrexed (Sandoz) | Pemetrexed (Sandoz) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Mar 17, 2023 | In Use | ||
J9314 | Pemetrexed (Teva) | Pemetrexed (Teva) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Dec 21, 2022 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.